Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw

被引:84
作者
Compston, J. [1 ]
机构
[1] Cambridge Univ Hosp NHS Fdn Trust, Cambridge CB2 0QQ, England
关键词
Atypical femoral fractures; Bisphosphonates; Denosumab; Microdamage; Osteonecrosis of the jaw; Suppression of bone turnover; BISPHOSPHONATE-RELATED OSTEONECROSIS; SUPPRESSED BONE TURNOVER; DIAPHYSEAL FEMUR FRACTURES; MICRODAMAGE ACCUMULATION; BIOMECHANICAL PROPERTIES; ZOLEDRONIC ACID; NONENZYMATIC GLYCATION; ALENDRONATE TREATMENT; POSTMENOPAUSAL WOMEN; MULTIPLE-MYELOMA;
D O I
10.1007/s00198-011-1804-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In recent years, atypical femoral fractures and osteonecrosis of the jaw have emerged as potential complications of long-term bisphosphonate therapy; osteonecrosis of the jaw has also been reported in patients receiving high doses of denosumab. The pathophysiology of both conditions is poorly defined, and the underlying mechanisms are likely to differ. The initiation of atypical fractures in the lateral femoral shaft suggests that reduced tensile strength, possibly secondary to alterations in the material properties of bone resulting from low bone turnover, may be an important pathogenetic factor. Osteonecrosis of the jaw is characterised by infection, inflammation, bone resorption and bone necrosis, but the sequence in which these occur has not been established. However, the observation that bone resorption occurs in close proximity to microbial structures suggests that infection may be the most important trigger, often as a result of dental disease. Other possible pathogenetic factors include suppression of bone turnover, altered immune status and adverse effects of bisphosphonates on the oral mucosa.
引用
收藏
页码:2951 / 2961
页数:11
相关论文
共 91 条
  • [1] Cumulative Alendronate Dose and the Long-Term Absolute Risk of Subtrochanteric and Diaphyseal Femur Fractures: A Register-Based National Cohort Analysis
    Abrahamsen, Bo
    Eiken, Pia
    Eastell, Richard
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (12) : 5258 - 5265
  • [2] Abrahamsen B, 2009, J BONE MINER RES, V24, P1095, DOI [10.1359/JBMR.081247, 10.1359/jbmr.081247]
  • [3] In vivo effects of zoledronic acid on oral mucosal epithelial cells
    Allam, E.
    Allen, M. R.
    Chu, T-M
    Ghoneima, A.
    Windsor, L. Jack
    [J]. ORAL DISEASES, 2011, 17 (03) : 291 - 297
  • [4] Allen M. R., 2007, Journal of Musculoskeletal & Neuronal Interactions, V7, P358
  • [5] Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra
    Allen, M. R.
    Gineyts, E.
    Leeming, D. J.
    Burr, D. B.
    Delmas, P. D.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2008, 19 (03) : 329 - 337
  • [6] Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment
    Allen, Matthew R.
    Burr, David B.
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 (11) : 1759 - 1765
  • [7] Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate
    Allen, Matthew R.
    Iwata, Ken
    Phipps, Roger
    Burr, David B.
    [J]. BONE, 2006, 39 (04) : 872 - 879
  • [8] The effects of bisphosphonates on jaw bone remodeling, tissue properties, and extraction healing
    Allen, Matthew R.
    [J]. ODONTOLOGY, 2011, 99 (01) : 8 - 17
  • [9] Bisphosphonates and Osteonecrosis of the Jaw: Moving from the Bedside to the Bench
    Allen, Matthew R.
    [J]. CELLS TISSUES ORGANS, 2009, 189 (1-4) : 289 - 294
  • [10] Bisphosphonate and nonbisphosphonate-associated osteonecrosis of the jaw A review
    Almazrooa, Soulafa A.
    Woo, Sook-Bin
    [J]. JOURNAL OF THE AMERICAN DENTAL ASSOCIATION, 2009, 140 (07) : 864 - 875